CJC-1295 – GHRH Research Peptide

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog studied for pituitary signaling mechanisms and GH secretion patterns in endocrinological research. This peptide exists in multiple configurations for differential pharmacokinetic profiling in laboratory models.

No DAC (Modified GRF 1-29): Unmodified analog with rapid clearance kinetics (half-life ~30 minutes) studied for pulsatile GH release patterns mimicking physiological secretion. Research examines acute receptor activation, signal transduction cascades, and short-duration hormonal responses in controlled settings.

With DAC (Drug Affinity Complex): Albumin-binding modification extending half-life to 6-8 days through reduced renal clearance. Investigated for sustained receptor occupancy, prolonged signaling dynamics, and continuous GH elevation profiles in extended-duration experimental protocols.

Combination with Ipamorelin: Dual-pathway GH research combining GHRH receptor agonism with ghrelin receptor (GHSR) activation. Studies characterize synergistic signaling effects, amplified secretory responses, and multi-receptor pathway interactions in pituitary cell models.

For laboratory research use only. Not for human consumption.